Pretty compelling, and importantly for surgeons, peer reviewed evidence for uptake of Remplir. Not quite the EOFY (Remplir sales) update most OCC holders were hoping for.
That to hopefully follow and that TGA CelGro Tendon (SmrtGraft) approval has not arrived bemuses me.
Ann: Compelling Data Highlights Remplir Competitive Advantage, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.010(0.78%) |
Mkt cap ! $309.6M | |||
| Open | High | Low | Value | Volume |
| $1.28 | $1.28 | $1.25 | $228.1K | 180.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 42250 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.28 | 3113 | 1 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| OCC (ASX) Chart |